Author/Editor		Jensterle, Mojca; Janež, Andrej; Kocjan, Tomaž; Pfeifer, Marija
Title		Sindrom policističnih ovarijev - metabolični vidik
Translated title		Metabolic aspects of polycystic ovary syndrome
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 76, št. 2
Publication year		2007
Volume		str. 109-16
Language		slo
Abstract		Polycystic ovary syndrome (PCOS) is one o f the most common eradocrinopathies, characterised by hyperandrogenism and chronic anovulation. Over the last twenty years, it has been widely recognized that in addition to endocrine and reproductive abnormalities, most women with PCOS demonstrate metabolic disturbances. This is not a surprising, finding, since insulin resistance (IR) followed by compensatory hyperinsulinemia has been recognized as the central pathogenetic, feature of the syndrome. Consequently, the PCOS women have higher rate and degree of impaired glucose tolerance, type 2 diabetes, central obesity, atherogenic dyslipidemia, arterial hypertension and even subclinical signs of atherosclerosis compared to age and weightmatched controls. They often have an adverse cardiovascular risk profile, characteristic of the metabolic syndrome. The knowledge about the association between IR and PCOS has been receyatly incorporated into the, framework ofPCOS treatment. There is increasing evidence that application of insulin sensitizingdrug_s, metformin and PPAR gamma agonists thiazolidinediones (TZDs), has favorable endocrine, reproductive and metabolic effects in PCO S. Recent developments and fW dings of the cardiometabolic abnormalities in patients with PCOS are reviewed here and the effects of insulin sensitizing drugs in this disorder are summarised, as well.
Summary		Sindrom policističnih ovarijev (PCOS) je ena najpogostejših endokrinih bolezni, za katero so značilni znaki androgenizacije in kronična anovulacija. V zadnjih dvajsetih letih je vedno več dokazov, da ima večina bolnic s PCOS poleg endokrinih in reproduktivnih motenj tudi metabolične motnje. Osrednja metabolična motnja je insulinska rezistenca (IR), ki ima s kompenzacijsko hiperinsulinemijo verjetno ključno etiopatogenetsko vlogo pri pomembnem deležu bolnic s PCOS. Posledično imajo bolnice s PCOS pogosteje kot zdrave kontrole moteno toleranco za glukozo, sladkorno bolezen tipa 11, centralno debelost, aterogeno dislipidemijo, arterijsko hipertenzijo in celo predklinične oblike ateroskleroze. Metabolične motnje so pogosto prisotne v obsegu metaboličnega sindroma in pomenijo povečano ogroženost teh bolnic za srčno-žilne bolezni. Sodobno zdravljenje PCOS ,je zato usmerjeno v izboljšanje občutljivosti za insulin. Znano je, da imajo zdravila, ki zmanjšujejo IR, metformin in agonisti PPARy iz skupine tiazolidindionov (TZD), zelo ugodne endokrine, reproduktivne in metabolične učinke pri bolnicah s PCOS. V preglednem članku bomo predstavili zadnja dognanja o metaboličnih motnjah pri holnicah s PCOS in povezave s srčno-žilnimi boleznimi. Povzeli homo izsledke o uspešnosti zdravljenja sindroma PCOS z zdravili, ki zmanjšujejo IR.
Descriptors		POLYCYSTIC OVARY SYNDROME INSULIN RESISTANCE OBESITY HYPERTENSION HYPERLIPIDEMIA METFORMIN